Equity Profile

NKTR

Nektar Therapeutics

Health CarePharmaceuticals$2.6B

Nov8Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EST

Company Snapshot

Nektar Therapeutics is a pharmaceutical company focused on developing innovative therapies for patients with serious diseases. With a market cap of $3 billion, it operates in the health care sector, which is currently seeing significant advancements in drug development and personalized medicine.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help gauge how well Nektar is managing its expenses and generating revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NKTR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

In the last quarter, Nektar reported an EPS of -$1.82, slightly missing analyst expectations. The stock reacted negatively, declining by 2.02% the following day.

Management Promises & Guidance

Management committed to advancing their clinical programs.
They emphasized a focus on cost management to improve future profitability.
Plans to provide more clarity on upcoming product launches.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Nektar's upcoming earnings report, hoping for signs of improved financial performance and progress in clinical trials.

Bull Case

If Nektar can demonstrate better-than-expected EPS and positive updates on clinical trials, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company reports larger-than-expected losses or delays in clinical trials, it may lead to a significant drop in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

The market will closely watch for any delays or advancements in clinical trials, as these can significantly impact future revenue potential.

How is the company managing its costs in light of recent losses?

Cost management will be critical for Nektar to improve its financial health and investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about Nektar's ability to manage costs and advance its clinical programs, underestimating the potential for operational improvements.

Supporting Evidence

The company's recent focus on cost management could lead to better-than-expected results.

Historical performance shows that Nektar has surprised positively in the past despite challenging circumstances.

Key Risk

If the company can show a path to reducing its EPS loss significantly, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

A reduction in EPS loss to below -$1.50 would indicate improved cost management and operational efficiency.

Bear Confirmed If

An EPS loss greater than -$2.00 would confirm ongoing financial struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±11.48%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±11.5% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

62.9%

Calls (67K)P/C Ratio: 1.63Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations, history suggests the stock could rise by around 1.58% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance from management.

Miss

A significant miss could lead to a decline of approximately 0.10%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for key clinical trials.
2Details on cost management strategies and their impact on future profitability.
3Any new partnerships or collaborations that could enhance product development.
4Management's outlook on market conditions and competitive landscape.
5Insights into the company's long-term strategic goals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

EOG Resources, Inc.

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help gauge how well Nektar is managing its expenses and generating revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NKTR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

In the last quarter, Nektar reported an EPS of -$1.82, slightly missing analyst expectations. The stock reacted negatively, declining by 2.02% the following day.

Management Promises & Guidance

Management committed to advancing their clinical programs.
They emphasized a focus on cost management to improve future profitability.
Plans to provide more clarity on upcoming product launches.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Nektar's upcoming earnings report, hoping for signs of improved financial performance and progress in clinical trials.

Bull Case

If Nektar can demonstrate better-than-expected EPS and positive updates on clinical trials, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company reports larger-than-expected losses or delays in clinical trials, it may lead to a significant drop in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

The market will closely watch for any delays or advancements in clinical trials, as these can significantly impact future revenue potential.

How is the company managing its costs in light of recent losses?

Cost management will be critical for Nektar to improve its financial health and investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about Nektar's ability to manage costs and advance its clinical programs, underestimating the potential for operational improvements.

Supporting Evidence

The company's recent focus on cost management could lead to better-than-expected results.

Historical performance shows that Nektar has surprised positively in the past despite challenging circumstances.

Key Risk

If the company can show a path to reducing its EPS loss significantly, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

A reduction in EPS loss to below -$1.50 would indicate improved cost management and operational efficiency.

Bear Confirmed If

An EPS loss greater than -$2.00 would confirm ongoing financial struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±11.48%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±11.5% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

62.9%

Calls (67K)P/C Ratio: 1.63Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations, history suggests the stock could rise by around 1.58% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance from management.

Miss

A significant miss could lead to a decline of approximately 0.10%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for key clinical trials.
2Details on cost management strategies and their impact on future profitability.
3Any new partnerships or collaborations that could enhance product development.
4Management's outlook on market conditions and competitive landscape.
5Insights into the company's long-term strategic goals.